Keyword: Xtandi

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.

Pfizer's mature drugs plunged in China. AZ and GSK race their oral anemia drugs to Asia. Biotech leaders worry IP crackdown will hurt collaboration.

Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to the FDA, they might not have to wait that long.

Analysts figure the Bayer drug's better safety profile could help it carve out market share against Pfizer and Astellas’ Xtandi and J&J’s Erleada.

Post-Upjohn Pfizer will focus on “bolt-on opportunities” mainly in the early- to mid-stage pipeline realm, CEO Albert Bourla said.

Pfizer and Astellas’ Xtandi is trying for a new indication, and they say Sunday's new data complement the evidence they’ve already generated.

Gearing up for the year's largest cancer confab, we break down the highlights to give you a glimpse of the studies we’re tracking, so you can follow along, too.

Johnson & Johnson has fallen behind the Pfizer-Astellas team with Erleada in the drug’s first approved indication. But now it looks poised to win another.

J&J and the Pfizer-Astellas team have grown accustomed to a two-horse race in prostate cancer. But it may not be long before a third joins them.

X marks the spot for Pfizer—that is, the spots where its products are struggling to live up to expectations.